Clinical Trial

A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This trial adopts a multicenter, open-label, positive drug parallel control clinical trial design, planning to enroll approximately 75 MF participants. Eligible participants will be stratified and assigned in a 1:1:1 ratio to the low-dose flonoltinib maleate tablet group, high-dose flonoltinib maleate tablet group, or the ruxolitinib tablet group. Stratification factor include the Dynamic International Prognostic Scoring System (DIPSS) risk classification (intermediate-2 and high risk)
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-08-13
notable Primary completion moved earlier: 2026-05-06 -> 2025-11-26 2026-08-13
minor Completion pushed: 2026-07-06 -> 2027-05-12 2026-08-13
Trial Details
NCT Number NCT06457425
Lead Sponsor Chengdu Zenitar Biomedical Technology Co., Ltd
Conditions MF,PMF,PPV-MF,PET-MF
Enrollment 75 participants
Start Date 2024-05-06
Primary Completion 2025-11-26 (estimated)
Study Completion 2027-05-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-12